NASDAQ · GLSI
Healthcare · Biotechnology
$16.46
Down-$0.95 (-5.46%)
Updated Nov 3, 2026, 11:00 AM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · GLSI
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
GLSI closed at $16.46 after 21 trading sessions, down 2.66% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $17.69 | $17.69 | $16.23 | $16.46 | 118.81K |
| Oct 30, 2026 | $18.47 | $18.77 | $17.04 | $17.41 | 174.65K |
| Oct 29, 2026 | $18.31 | $19.50 | $18.08 | $19.00 | 124.12K |
| Oct 28, 2026 | $17.22 | $18.44 | $17.00 | $18.31 | 130.03K |
| Oct 27, 2026 | $17.19 | $17.58 | $16.6588 | $17.42 | 224.3K |
| Oct 26, 2026 | $16.01 | $17.44 | $15.855 | $17.125 | 118.89K |
| Oct 23, 2026 | $15.40 | $16.09 | $14.785 | $16.03 | 86.52K |
| Oct 22, 2026 | $16.02 | $16.77 | $15.2088 | $15.48 | 96.44K |
| Oct 21, 2026 | $16.41 | $16.67 | $16.16 | $16.57 | 82.27K |
| Oct 20, 2026 | $15.10 | $16.435 | $15.10 | $16.24 | 101.57K |
| Oct 19, 2026 | $14.84 | $15.39 | $14.75 | $15.21 | 151.94K |
| Oct 16, 2026 | $15.30 | $15.53 | $14.41 | $14.55 | 107.7K |
| Oct 15, 2026 | $15.12 | $15.605 | $15.10 | $15.32 | 81.36K |
| Oct 14, 2026 | $15.25 | $16.35 | $15.15 | $15.40 | 137.83K |
| Oct 13, 2026 | $17.50 | $17.75 | $14.06 | $15.50 | 317.68K |
| Oct 12, 2026 | $16.45 | $18.00 | $16.42 | $17.77 | 163.23K |
| Oct 9, 2026 | $15.20 | $16.80 | $15.20 | $16.53 | 119.88K |
| Oct 8, 2026 | $15.29 | $16.1399 | $14.55 | $15.14 | 129.1K |
| Oct 7, 2026 | $15.81 | $16.37 | $15.00 | $15.39 | 147.56K |
| Oct 6, 2026 | $17.02 | $17.32 | $15.40 | $15.79 | 113.65K |
| Oct 5, 2026 | $16.92 | $17.25 | $16.26 | $16.91 | 98.73K |
The latest Smart Investors Daily articles mentioning GLSI.
Company
Market Activity
Research & News
GLSI research
Company profile and research snapshot.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 21, 2026 | HC Wainwright & Co. | Buy | — |
| Dec 30, 2025 | HC Wainwright & Co. | Buy | — |
| Apr 21, 2025 | HC Wainwright & Co. | Buy | — |
| Feb 11, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 23, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Finnhub · Apr 30, 2026
STAFFORD, Texas, April 30, 2026 -- Greenwich LifeSciences, Inc. , a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track...
Benzinga · Mar 19, 2026
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an
Benzinga · Mar 18, 2026
Benzinga · Mar 17, 2026
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GLSI.
